U.S. markets close in 1 hour 52 minutes

Adaptimmune Therapeutics plc (ADAP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.5650-0.1850 (-3.89%)
As of 2:05PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Outside Bar (Bearish)

Outside Bar (Bearish)

Previous Close4.7500
Open4.7800
Bid4.5600 x 3100
Ask4.5700 x 900
Day's Range4.5000 - 4.7800
52 Week Range1.0300 - 13.4000
Volume1,049,497
Avg. Volume1,303,014
Market Cap706.566M
Beta (5Y Monthly)2.48
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 2 Cancer Stocks That Could Make You Filthy Rich
    Motley Fool

    2 Cancer Stocks That Could Make You Filthy Rich

    The core reason is that most of these companies are trading at a mere fraction of the commercial potential of their lead product candidates. On the rare occasion, however, these risky equities do sprout wings and learn to fly because of a surprise win in the clinic, a buyout agreement, or a licensing deal with a bigger pharma -- thus producing outsize gains for early shareholders. Adaptimmune Therapeutics (NASDAQ: ADAP) and Trillium Therapeutics (NASDAQ: TRIL) could both turn out to be diamonds in the rough.

  • Adaptimmune Therapeutics PLC (ADAP) Q3 2020 Earnings Call Transcript
    Motley Fool

    Adaptimmune Therapeutics PLC (ADAP) Q3 2020 Earnings Call Transcript

    Image source: The Motley Fool. Adaptimmune Therapeutics PLC (NASDAQ: ADAP)Q3 2020 Earnings CallNov 6, 2020, 8:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, thank you for standing by, and welcome to Adaptimmune's Third Quarter 2020 Financial Results and Business Update.

  • Why Adaptimmune Therapeutics Stock Is Sinking Today
    Motley Fool

    Why Adaptimmune Therapeutics Stock Is Sinking Today

    Adaptimmune Therapeutics (NASDAQ: ADAP), a clinical-stage cancer specialist, is having another off day today. For the week, Adaptimmune's stock is now down by over 20%. Earlier today, Adaptimmune announced the early release of an abstract for an upcoming presentation at the virtual Society for the Immunotherapy of Cancer conference on Nov. 11, 2020.